Compare Incyte Corporation (INCY) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Wipro Limited — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Wipro Limited trades at $1.87 (market cap $18.49B). The key difference: Incyte Corporation is the larger of the two by market cap, and Wipro Limited pays a 4.68% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | WIT | |
|---|---|---|
Market Cap | $23.11B | $18.49B |
Sector | Health | Technology |
52-Week High | $118.52 | $3.06 |
52-Week Low | $67.38 | $1.82 |
Enterprise Value | $19.13B | $16.42B |
Dividend Yield | — | 4.68% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
